Skip to main content

Table 14 The cost-effectiveness analysis in the 24-month period (reversion rate)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group C(yuan) E (%) C/E ΔC/ΔE
The treatment group 41367830.8 45.1 917246.8  
The control group 37529823.2 30 1250994.1 254172.7